Microplastics have become the world\'s most emerging pollutants today due to the ubiquitous use of plastics in everyday life and their ability to migrate from micro to nanoscale to every corner of the natural world, leading to ecological imbalances and global catastrophes. However, a standardized method for separating and analyzing microplastics from actual food or environmental samples has not been established. Therefore, it is necessary to develop a simple, fast, cost-effective, and accurate method that can accurately measure the degree of contamination of microplastics. As one of these methods, fluorometry has been proposed as a cost-effective method to detect, quantify and differentiate individual plastic particles. Therefore, this review discussed the technique for analyzing microplastics using fluorescent carbon dots (CDs). This review provided an overview of the impact of microplastics and the feasibility of using CDs to detect and analyze microplastics. In particular, this review will discuss novel microplastic analysis methods using CD and future application studies. The method using CDs will overcome the limitations of current microplastic analysis technology and may become a new method for detecting and analyzing microplastics.

BACKGROUND: Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or delays in accessing care can limit opportunities to monitor disease trajectory and response to treatment, and the COVID-19 pandemic has added to these challenges. Therefore, home monitoring technologies, such as home handheld spirometry, have gained increased attention as they may help to improve access to care for patients with ILD. However, while several studies have shown that home handheld spirometry in ILD is acceptable for most patients, data from clinical trials are not sufficiently robust to support its use as a primary endpoint. This review discusses the challenges that were encountered with handheld spirometry across three recent ILD studies, which included home spirometry as a primary endpoint, and highlights where further optimisation and research into home handheld spirometry in ILD is required. Rate of decline in forced vital capacity (FVC) as measured by daily home handheld spirometry versus site spirometry was of primary interest in three recently completed studies: STARLINER (NCT03261037), STARMAP and a Phase II study of pirfenidone in progressive fibrosing unclassifiable ILD (NCT03099187). Unanticipated practical and technical issues led to problems with estimating FVC decline. In all three studies, cross-sectional correlations for home handheld versus site spirometry were strong/moderate at baseline and later timepoints, but longitudinal correlations were weak. Other issues observed with the home handheld spirometry data included: high within-patient variability in home handheld FVC measurements; implausible longitudinal patterns in the home handheld spirometry data that were not reflected in site spirometry; and extreme estimated rates of FVC change.
CONCLUSIONS: Home handheld spirometry in ILD requires further optimisation and research to ensure accurate and reliable FVC measurements before it can be used as an endpoint in clinical trials. Refresher training, automated alerts of problems and FVC changes, and patient support could help to overcome some practical issues. Despite the challenges, there is value in incorporating home handheld spirometry into clinical practice, and the COVID-19 pandemic has highlighted the potential for home monitoring technologies to help improve access to care for patients with ILD.

The global concern over the possible consequences of the downsizing of plastic to microplastics (MPs) and nano plastics (NPs) needs to be addressed with a new conceptual framework. The transformation of plastics to MPs and NPs can be discussed in terms of fundamental physics principles applicable to micro and nanophase matter and colloidal science principles. Further, accurate and reliable detection and characterization of MPs and NPs are crucial for an extensive understanding of their environmental and ecological impacts. The other decisive factor that can classify MPs and NPs as hazardous to existing nanomaterials is discussing the cytotoxicity study on human cell lines. The human health risk assessment that might arise from the ingestion of MPs and NPs can be addressed about contrast agents used for medical imaging. However, the lack of standard analytical techniques for MPs and NPs measurement is an emerging challenge for analytical scientists due to their complex physicochemical properties, especially in environmental samples. This review article navigates readers through the point of origin of MPs and NPs and their interdisciplinary aspects. Biomedical applications of plastics and concerns over the toxicity of MPs and NPs are further analyzed. Moreover, the analytical challenges of MPs and NPs have been discussed with critical inputs. Finally, the worldwide efforts being made for creating a common platform of discussion on a different aspect of plastic pollution were taken into account.

Circular RNAs (circRNAs) are a distinct family of RNAs derived from the non-regular process of alternative splicing. CircRNAs have recently gained interest in transcriptome research due to their potential regulatory functions during gene expression. CircRNAs can act as microRNA sponges and affect transcription through their complex involvement in regular transcriptional processes. Some early studies also suggested significant roles for circRNAs in human diseases, especially cancer, as biomarkers and potential clinical targets. Therefore, there is a great need for laboratory scientists to translate these findings into clinical tools to advance testing for human diseases. To facilitate a better understanding of the promise of circRNAs, we focus this review on selected basic aspects of circRNA research, specifically biogenesis, function, analytical issues regarding identification and validation and examples of expression data in relation to human diseases. We further emphasize the unique challenges facing laboratory medicine with regard to circRNA research, particularly in the development of robust assays for circRNA detection in different body fluids and the need to collaborate with clinicians in the design of clinical studies.